Estrogen Therapy: Economic Considerations
Posted on March 12, 2018
The high cost of health care for untreated menopausal women continues to be a subject of current interest. The NAMS 2017 Hormone Therapy Position Statement section on Economic Considerations describes the association between moderate to severe vasomotor symptoms (VMS) "with lower levels of health status and work productivity and greater use of health resources."
Women with untreated VMS show increased direct healthcare costs, and also indirect costs related to impaired work ability and work loss. Driven by menopause-related symptoms and disease, the combined costs for office and emergency room visits, pharmacy, and hospitalization are substantial.